Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary

J Dermatol. 2020 Jun;47(6):e237-e239. doi: 10.1111/1346-8138.15341. Epub 2020 Apr 9.

Authors

Jiro Uehara¹, Koji Yoshino¹, Eiki Sugiyama¹, Kaori Ohkuma¹, Satoe Oaku¹, Chisato Yamashita¹, Azusa Hiura¹, Yasuhiro Fujisawa²

Affiliations

¹ Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
² Department of Dermatology, University of Tsukuba, Ibaraki, Japan.

PMID: 32270507
DOI: 10.1111/1346-8138.15341

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Biopsy
Bone Marrow / drug effects
Bone Marrow / immunology
Bone Marrow / pathology
CTLA-4 Antigen / antagonists & inhibitors
CTLA-4 Antigen / immunology
Female
Humans
Immune Checkpoint Inhibitors / adverse effects*
Ipilimumab / adverse effects*
Melanoma / drug therapy
Melanoma / immunology
Melanoma / secondary
Neoplasms, Unknown Primary / drug therapy
Neoplasms, Unknown Primary / immunology
Nivolumab / adverse effects*
Pancytopenia / blood
Pancytopenia / chemically induced
Pancytopenia / diagnosis*
Pancytopenia / immunology
Skin Neoplasms / drug therapy
Skin Neoplasms / immunology
Skin Neoplasms / secondary
T-Lymphocytes, Regulatory / drug effects
T-Lymphocytes, Regulatory / immunology

Substances

CTLA-4 Antigen
CTLA4 protein, human
Immune Checkpoint Inhibitors
Ipilimumab
Nivolumab